MX2017007390A - Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. - Google Patents

Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales.

Info

Publication number
MX2017007390A
MX2017007390A MX2017007390A MX2017007390A MX2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A
Authority
MX
Mexico
Prior art keywords
neoplasms
central nervous
immune checkpoint
checkpoint inhibitors
nervous systems
Prior art date
Application number
MX2017007390A
Other languages
English (en)
Spanish (es)
Inventor
Coric Vladimir
CHENG Shinta
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2017007390A publication Critical patent/MX2017007390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2017007390A 2014-12-16 2015-12-16 Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. MX2017007390A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092783P 2014-12-16 2014-12-16
US201562261130P 2015-11-30 2015-11-30
PCT/US2015/066177 WO2016100561A2 (en) 2014-12-16 2015-12-16 Use of immune checkpoint inhibitors in central nervous systems neoplasms

Publications (1)

Publication Number Publication Date
MX2017007390A true MX2017007390A (es) 2017-11-06

Family

ID=56127849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007390A MX2017007390A (es) 2014-12-16 2015-12-16 Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales.

Country Status (9)

Country Link
US (3) US20180133313A1 (enExample)
EP (1) EP3233123A4 (enExample)
JP (2) JP2018500332A (enExample)
CN (1) CN106999590A (enExample)
BR (1) BR112017010101A2 (enExample)
CA (1) CA2969338A1 (enExample)
MX (1) MX2017007390A (enExample)
RU (1) RU2726996C1 (enExample)
WO (1) WO2016100561A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
JP7250674B2 (ja) * 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
AU2017372856B9 (en) * 2016-12-05 2024-01-04 Pharmacosmos Holding A/S Preservation of immune response during chemotherapy regimens
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
DE102017119868B4 (de) * 2017-07-12 2021-05-27 Bruker Daltonik Gmbh Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie
US10617667B2 (en) * 2017-11-01 2020-04-14 Ono Pharmaceutical Co., Ltd. Method for treating brain tumors
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
JP7388635B2 (ja) 2018-05-31 2023-11-29 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
EP3941467A4 (en) * 2019-03-19 2022-12-21 ChemoCentryx, Inc. MULTIPLE THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
WO2021050093A1 (en) * 2019-09-10 2021-03-18 Novocure Gmbh A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells
JP7772700B2 (ja) * 2019-12-19 2025-11-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 神経膠芽腫を処置するための方法
CN114980930A (zh) * 2019-12-27 2022-08-30 志瑞亚新药工业株式会社 癌症治疗方法及药物
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
JP2023526228A (ja) * 2020-05-12 2023-06-21 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 膠芽腫を処置するための方法
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20230365690A1 (en) * 2020-08-07 2023-11-16 Northwestern University Methods of treating malignant glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545609T3 (es) * 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
PL2342226T3 (pl) * 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
RU2402360C1 (ru) * 2009-07-08 2010-10-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения злокачественной глиомы головного мозга
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
AU2012273182A1 (en) * 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
AU2013263076B2 (en) * 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Also Published As

Publication number Publication date
US20240238416A1 (en) 2024-07-18
CN106999590A (zh) 2017-08-01
WO2016100561A3 (en) 2016-08-18
EP3233123A2 (en) 2017-10-25
US20210000953A1 (en) 2021-01-07
JP2021181482A (ja) 2021-11-25
WO2016100561A2 (en) 2016-06-23
EP3233123A4 (en) 2018-05-09
CA2969338A1 (en) 2016-06-23
US20180133313A1 (en) 2018-05-17
RU2726996C1 (ru) 2020-07-17
BR112017010101A2 (pt) 2018-01-02
JP2018500332A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
WO2016100561A3 (en) Use of immune checkpoint inhibitors in central nervous systems neoplasms
MX2022002364A (es) Anticuerpos anti-pd-l1.
NZ728688A (en) Anti-pd-1 antibodies
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
PL3322731T3 (pl) Sposób leczenia raka inhibitorem immunologicznych punktów kontrolnych; przeciwciałem, które wiąże się z receptorem programowanej śmierci-1 (pd-1) lub ligandem receptora programowanej śmierci 1 (pd-l1)
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
EP3572430A3 (en) Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
EA201790926A1 (ru) Комбинированное лечение злокачественного новообразования
JOP20200003B1 (ar) أجسام مضادة ثنائية النوعية مثبطة لنقاط مراقبة المناعة
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX2017000857A (es) Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
EA201691376A1 (ru) Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
NZ728674A (en) Signalling system
MX2015012428A (es) Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios.
CO2017012988A2 (es) Agentes, usos y métodos para el tratamiento
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
IL250137A0 (en) Method for inhibiting intracellular activated ras using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
MX2019005089A (es) Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso.
MX2017007097A (es) Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
TW201613957A (en) Factor X activation